author-photo

Astrid Gruber

Karolinska Institutet
Karolinska University Hospital

118

Papers

3748

Citations

Citation Trend

Filter By

Papers (77) Sort By

Journal Conference Others

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial

2018 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (10)
Abstract 5030: The impact ofABCB1single nucleotide polymorphisms on the outcome in lenalidomide treated multiple myeloma patients

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Acute Myelogenous Leukemia Cells Secrete Factors that Stimulate Cellular LDL Uptake via Autocrine and Paracrine Mechanisms

2017 Lipids
Show All
- Source
- Cite
- Save
Citations (2)
Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group

2017 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.

2016 Blood
Show All
- Source
- Cite
- Save
Citations (74)
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial

2015 Bone Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (13)
Re-Challenging with Anti-CD38 Monotherapy in Triple-Refractory Multiple Myeloma Patients Is a Feasible and Safe Approach

2015 Blood
Show All
- Source
- Cite
- Save
Citations (0)
The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

2015 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG)

2014 Blood
Show All
- Source
- Cite
- Save
Citations (7)
THE REVII TRIAL : LENALIDOMIDE AND DEXAMETHASONE AS SECOND LINE TREATMENT IN MYELOMA FOLLOWED BY EXTENDED LENALIDOMID VS LEN/DEX

2014
Show All
- Source
- Cite
- Save
Citations (0)